Michelle E Fullard1,2, Baochan Tran2, Lama M Chahine2, James F Morley1,2, Sharon X Xie3, Jon B Toledo4, Christi Scordia2, Carly Linder2, Rachael Purri2, Daniel Weintraub1,2,5, John E Duda1,2. 1. Parkinson's Disease Research, Education, and Clinical Center (PADRECC), Philadelphia VA Medical Center, 3900 Woodland Ave, Philadelphia, PA 19104, USA. 2. Department of Neurology, Perelman School of Medicine at the University of Pennsylvania, 3400 Spruce Street, Philadelphia, PA 19104, USA. 3. Department of Biostatistics and Epidemiology, Perelman School of Medicine at the University of Pennsylvania, 423 Guardian Drive, Philadelphia, PA 19104, USA. 4. Department of Pathology & Laboratory Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, 3400 Spruce Street, Philadelphia, PA 19104, USA. 5. Department of Psychiatry, Perelman School of Medicine at the University of Pennsylvania, 3400 Spruce Street, Philadelphia, PA 19104, USA.
Abstract
OBJECTIVE: To evaluate the association between baseline olfaction and both cross-sectional and longitudinal cognitive assessments, motor symptoms, non-motor symptoms (NMS), and CSF biomarkers in early Parkinson's disease (PD). METHODS: Parkinson's Progression Marker's Initiative (PPMI) participants underwent baseline olfactory testing with the University of Pennsylvania Smell Identification Test (UPSIT). Serial assessments included measures of motor symptoms, NMS, neuropsychological assessment, and CSF biomarkers. Up to three years follow-up data were included. RESULTS: At baseline, worse olfaction (lowest tertile) was associated with more severe NMS, including anxiety and autonomic symptoms. Those in the lowest olfactory tertile were more likely to report cognitive impairment (37.4%) compared to those in the middle (24.4%) and highest olfactory tertiles (14.2%, p < 0.001). Aβ1-42 was significantly lower, and tau/Aβ1-42 ratio was higher in those with worse olfaction. In longitudinal analyses, lower UPSIT score was associated with greater decline in MoCA score (β = 0.02 [0.01, 0.03], p = 0.001) over time, as were composite measures of UPSIT score and either Aβ1-42 or tau/Aβ1-42 ratio. In a Cox proportional hazards model, a composite measure of olfaction and Aβ1-42 was a significant predictor of conversion from normal cognition to mild cognitive impairment (MCI; i.e., MoCA < 26), with subjects most impaired on both measures being 87% more likely to develop incident MCI (HR = 1.87 [1.16, 3.01], p = 0.01). CONCLUSIONS: Worse baseline olfaction is associated with long-term cognitive decline. The addition of AD CSF biomarkers to olfactory testing may increase the likelihood of identifying those at highest risk for cognitive decline and progression to MCI. Published by Elsevier Ltd.
OBJECTIVE: To evaluate the association between baseline olfaction and both cross-sectional and longitudinal cognitive assessments, motor symptoms, non-motor symptoms (NMS), and CSF biomarkers in early Parkinson's disease (PD). METHODS:Parkinson's Progression Marker's Initiative (PPMI) participants underwent baseline olfactory testing with the University of Pennsylvania Smell Identification Test (UPSIT). Serial assessments included measures of motor symptoms, NMS, neuropsychological assessment, and CSF biomarkers. Up to three years follow-up data were included. RESULTS: At baseline, worse olfaction (lowest tertile) was associated with more severe NMS, including anxiety and autonomic symptoms. Those in the lowest olfactory tertile were more likely to report cognitive impairment (37.4%) compared to those in the middle (24.4%) and highest olfactory tertiles (14.2%, p < 0.001). Aβ1-42 was significantly lower, and tau/Aβ1-42 ratio was higher in those with worse olfaction. In longitudinal analyses, lower UPSIT score was associated with greater decline in MoCA score (β = 0.02 [0.01, 0.03], p = 0.001) over time, as were composite measures of UPSIT score and either Aβ1-42 or tau/Aβ1-42 ratio. In a Cox proportional hazards model, a composite measure of olfaction and Aβ1-42 was a significant predictor of conversion from normal cognition to mild cognitive impairment (MCI; i.e., MoCA < 26), with subjects most impaired on both measures being 87% more likely to develop incident MCI (HR = 1.87 [1.16, 3.01], p = 0.01). CONCLUSIONS: Worse baseline olfaction is associated with long-term cognitive decline. The addition of ADCSF biomarkers to olfactory testing may increase the likelihood of identifying those at highest risk for cognitive decline and progression to MCI. Published by Elsevier Ltd.
Authors: D Verbaan; S Boesveldt; S M van Rooden; M Visser; J Marinus; M G Macedo; Y Fang; P Heutink; H W Berendse; J J van Hilten Journal: Neurology Date: 2008-12-02 Impact factor: 9.910
Authors: Mariese A Hely; Wayne G J Reid; Michael A Adena; Glenda M Halliday; John G L Morris Journal: Mov Disord Date: 2008-04-30 Impact factor: 10.338
Authors: Ju-Hee Kang; David J Irwin; Alice S Chen-Plotkin; Andrew Siderowf; Chelsea Caspell; Christopher S Coffey; Teresa Waligórska; Peggy Taylor; Sarah Pan; Mark Frasier; Kenneth Marek; Karl Kieburtz; Danna Jennings; Tanya Simuni; Caroline M Tanner; Andrew Singleton; Arthur W Toga; Sohini Chowdhury; Brit Mollenhauer; John Q Trojanowski; Leslie M Shaw Journal: JAMA Neurol Date: 2013-10 Impact factor: 18.302
Authors: Yaroslau Compta; Laura Parkkinen; Sean S O'Sullivan; Jana Vandrovcova; Janice L Holton; Catherine Collins; Tammaryn Lashley; Constantinos Kallis; David R Williams; Rohan de Silva; Andrew J Lees; Tamas Revesz Journal: Brain Date: 2011-05 Impact factor: 13.501
Authors: Carla Masala; Paolo Solla; A Liscia; G Defazio; L Saba; A Cannas; A Cavazzana; T Hummel; A Haehner Journal: J Neurol Date: 2018-05-26 Impact factor: 4.849
Authors: Daniel Weintraub; Lana M Chahine; Keith A Hawkins; Andrew Siderowf; Shirley Eberly; David Oakes; John Seibyl; Matthew B Stern; Kenneth Marek; Danna Jennings Journal: Mov Disord Date: 2017-10-24 Impact factor: 10.338
Authors: Dominic H Ffytche; Joana B Pereira; Clive Ballard; K Ray Chaudhuri; Daniel Weintraub; Dag Aarsland Journal: J Neurol Neurosurg Psychiatry Date: 2017-04 Impact factor: 10.154